



Annual General Meeting

Reykjavik - 4 April 2007



Today's speakers

Thor Bjorgolfsson, Chairman
Robert Wessman, President & CEO



Forward looking statement

Any statement contained in this presentation that refers to Actavis' estimated or anticipated future results or future activities are forward-looking statements which reflect the Company's current analysis of existing trends, information and plans. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially depending on factors such as the availability of resources, the timing and effect of regulatory actions, the success of new products, the strength of competition, the success of research and development issues, unexpected contract breaches or terminations, exposure to product liability and other lawsuits, the effect of currency fluctuations and other factors. Actavis does not undertake the obligation to update or alter these forward-looking statements beyond its duties as an issuer of listed securities on the Iceland Stock Exchange.



Today's speakers



Thor Bjorgolfsson
Chairman



Robert Wessman
President & CEO

Chairman's report

Thor Bjorgolfsson
Chairman of the Board



Chief Executive's report

Robert Wessman
President & CEO



Another strong year for Actavis

Twelve Months ended 31 December			
Thousands of Euro	12M 2006	12M 2005	% change
Total revenue.....	1,379,921	579,264	138.2%
EBITDA.....	287,134	148,471	93.4%
EBITDA %.....	20.8%	25.6%	(4.8%)
Underlying net income.....	148,819	86,679	71.7%
Net income after PPA & Pliva effect.....	102,689	81,003	26.8%
Pro-forma underlying revenue growth.....	9.4%		
Underlying diluted earnings per share.....	0.03190	0.02734	16.7%

- Underlying net income has been calculated prior to the impact of costs related to the PLIVA transaction and to the amortisation of purchased intangibles
- Pro forma underlying growth, includes underlying growth from businesses acquired in 2005 to reflect the growth of the business as it is today, at constant exchange rates.
- Calculation of diluted EPS is in euros and takes full account of preferred shares and their dividend payments.



Major achievements 2006



Sindan
Romania



ZIO Zdorovje
Russia



Abrika
USA



Grandix
India

- Four strategic acquisitions
- 376 product launches, 38 ANDA filings in US
- Investment of EUR70 million in expansion and upgrades of factories
- Divestment of manufacturing plant in Lier in Norway
- Distribution outsourced in the US and Baltimore facility to be closed in 2008
- Foundation for full backward integration in India
- Significant synergies achieved through Alpharma integration



Major achievements 2006 - cont.

Forward integration:

- Higia, Pharma EXPERT® over *200 Pharmacies in Bulgaria*
- Cooperation solution for independent pharmacies




Awards 2006

The Group received a total of **14 awards** in different countries and different categories.



Balance sheet Assets

EUR million




Trade receivables	224.2	255.5
Other intangibles	504.2	535.6
Other fixed assets	467.3	422.8
Other current assets	169.8	164.8
Inventories	277.9	250.2
Goodwill	936.1	902.6
Total Assets	2,579.4	2,531.4

Balance sheet Equity & liabilities

EUR million

Net Debt = EUR1,151m
Net Debt : EBITDA (12 month rolling) = 3.96 x



Current liabilities	564.6	380.6
Non-current liabilities	1,125.1	1,189.4
Minority interest	9.5	11.6
Stockholders' equity	880.2	949.8
Total shareholder equity	2,579.4	2,531.4

Sources of cash flow

Euro million

	12M 2006
Profit for the period.....	102.7
Depreciation and amortisation.....	89.6
Other adjustments.....	11.9
Working capital from operating activities.....	204.1
Changes in operating assets and liabilities.....	
Receivables.....	(6.4)
Inventories.....	(52.0)
Payables.....	16.2
Net change in operating assets and liabilities.....	(42.2)
Net Cash provided by operating activities.....	161.9

Year end trade receivables < 60 days
Inventory turns 3 x



Uses of cash flow

Euro million


	12M 2006
Net Cash provided by operating activities.....	161.9
Investment in property, plant and equipment	(96.8)
Proceeds from sale of fixed assets	17.0
Net Increase in intangibles	(64.6)
Net free cash flow.....	17.5
Acquisitions.....	(187.0)
Net cash used.....	(331.4)
Changes in net debt.....	249.9
Changes in capital stock.....	(98.5)
Net financing.....	151.4
Net change in cash and cash equivalents.....	(18.0)
Effects of foreign exchange adjustments.....	(3.0)
Cash and cash equivalents at beginning of period.....	99.3
Cash and cash equivalents at end of period.....	78.3

EUR95 m treasury stock purchased in 4Q

Strategic positioning



Well placed in key markets



* Breakdown of sales includes sales and distribution of finished goods
 * Revenues in Bulgaria include the distribution business of Higia, acquired in 2005



Dynamic pipeline

End of 2006

	EU	US	ROW	Total
Development projects	121	134	19	274
Molecules	76	103	7	186
Ongoing registrations	26	55		81

Early Development	Full Development	Biostudy / Stability	Registration
96	133	45	81

Total pipeline: 355 projects




Growing presence in India Fully integrated

- Fully operational API research center in Bangalore - 50 employees
 - 15-20 DMF's a year
- Strong CRO business with over 200 bio-studies a year
- Analytical lab to support global stability studies
- Total of 620 employed in India




Global generic revenue positioning



Sources Used: 2006 Company Interim Financial Reports, SEC filings and Internal Estimates. Generic Definition: The individual company's own definition of their generic segment was utilized where given. APL Chemicals, as well as other non-human pharma segments as could be estimated were not included in the Generic revenues. *** Actavis does include sales from the Abrila acquisition which occurred after YTD 9 Months 2006. ** Watson does not include the generic sales of Andex which was acquired after YTD 9 months. Andex generic segment's sales for YTD 9 months 2006 were not available, but they are estimated to be around \$200 mln based on YTD 6 Months 2006 and 2005. The % increase for Watson would be around 45% being privately held. Ratiopharm's YTD 9 months revenue was not available. For 2005 their sales were reported in Norddeutsche Zeitung, Don Jones S.306, to be estimated at €160 mln. For inclusion in the chart 1/3 of that revenue or €120 mln was included in this overview. Exchange rates used were €2K to Euro 0.01891. Euro to USD 1.344.

Critical mass important Aim for top-5 in key markets



Sources: Bulgaria, Norway, Sweden, Denmark, Finland, Portugal, Turkey, Netherlands - IMS Dataview 2006; UK - IMS BGMA data at Tariff value price level; For volume, Actavis is #2; Russia - Pharmaexpert 2006; Serbia - IMS 2005 Data, USA IMS US 2006 - IMS Prescription Audit - New and refilled prescriptions.

Financial guidance





2007 Guidance

- **EUR1.6 billion** in revenues
 - Underlying growth of 13%
 - Double digit growth in CEEA, Third-party and WEMEA
- **EBITDA margin** of 21-22%
- Over **500** product and market launches
- **40-45 ANDA filings** in 2007 for the US market
- **Revenue and EBITDA** higher in second half than in first half
 - Active launch schedule and marketing campaigns in first half
 - Growing contribution from Abrika and Zio Zdorovje



Financial targets 2007-2009

- Over **EUR1.9 billion** in revenues by end of 2009
- Improving COGS by **3% points** from 2006 to 2009
- EBITDA margin growing from 20.8% in 2006 to **25%** by end of 2009
- **20%+** annual growth in diluted EPS in 2007-2009
- Gaining **top 5 position** in key markets by end of 2009



AGM proposals



Tillögur/Proposals

Allotment of dividends

- The Board of Directors of Actavis Group hf. proposes that no dividends be paid out for the year 2006, but the Company's profit for the year allocated to increase the equity of the Company.

Tillaga félagsstjórnar um arðgreiðslur

- Stjórn Actavis Group hf. leggur til að ekki verði greiddur út arður fyrir árið 2006, heldur verði hagnaði félagsins á árinu ráðstafað til hækkunar eigin fjár félagsins.



Tillögur/Proposals

Remuneration to the members of the Board

- The Annual General Meeting of Actavis Group hf., held on 4 April 2007, approves that the remuneration of the Board of Directors in 2007 will be as follows:
 - Chairman of the Board ISK 600,000 per month, other Directors ISK 300,000 per month.
 - Alternate Directors ISK 50,000 per meeting they attend.

Tillaga um þóknun til stjórnarmanna fyrir næsta kjörtímabil

- Aðalfundur Actavis Group hf. haldinn 4. apríl 2007 samþykkir að stjórnarlaun vegna ársins 2007 verði sem hér segir:
 - Stjórnarformaður kr. 600.000 á mánuði, en aðrir stjórnarmenn kr. 300.000 á mánuði.
 - Varastjórnarmenn kr. 50.000 fyrir hvern fund sem þeir sitja.



Tillögur/Proposals

Candidates for the board

Frambjóðendur til stjórnar

- Björgólfur Thor Björgólfsson
- Magnús Þorsteinsson
- Andri Sveinsson
- Sindri Sindrason
- Vilhelm Róbert Wessman

Reserve board member

Frambjóðandi til varastjórnar

- Baldur Guðnason



Tillögur/Proposals

Auditing firm

- It is proposed that KPMG hf., reg. no. 590975-0449, be re-elected as the Company's auditing firm for 2007.
- The Annual General Meeting authorises the Board of Directors to get offers from three auditing companies, KPMG hf., Deloitte hf. and PricewaterhouseCoopers hf., regarding the auditing of the group and approve the offer which is in the opinion of the Board most favourable.

Tillaga félagsstjórnar um endurskoðunarfélag

- Lagt er til að KPMG hf., kt. 590975-0449, verði endurkjörð endurskoðunarfélag Actavis Group hf. fyrir árið 2007.
- Aðalfundur félagsins heimilar félagsstjórn að leita tilboða frá þremur endurskoðunarfélögum, KPMG hf., Deloitte hf. og PricewaterhouseCoopers hf., um endurskoðun á samstæðu félagsins og taka því tilboði sem hagstæðast er að mati stjórnar.



Tillögur/Proposals

Remuneration policy

- The below Remuneration Policy of Actavis Group hf. is based on the current Act on Public Limited Companies, general principles on corporate governance and long-term aspects of growth and maximization of profits for the Company's shareholders.

Tillaga stjórnar um starfskjarastefnu

- Starfskjarastefna Actavis Group hf. hér að neðan byggir á nügildandi hlutafélagalögum, meginreglum sem gilda um góða stjórnarhætti fyrirtækja og langtímasjónarmiðum um vöxt og hámarks arðsemi fyrir hluthafa félagsins.



Tillögur/Proposals

Remuneration policy, cont.

- For this purpose, Actavis Group hf. places high emphasis on enabling the Company to keep its key-employees and that desirable employees are willing to work for the Company, as such employees are the precondition for its continuing growth and the maintenance of its strong position in Iceland, as well as abroad.

Tillaga stjórnar um starfskjarastefnu, frh.

- Actavis Group hf. leggur í þessu skyni ríka áherslu á að félagið sé í stakk búið að halda í lykilstarfsmenn sína og að öflugir starfsmenn faist til starfa fyrir félagið, þar sem þeir eru forsenda áframhaldandi vaxtar og sterkrar stöðu þess á Íslandi, sem og erlendis.



Tillögur/Proposals

Remuneration policy, cont.

- Board members shall receive a fixed fee for their services. The amount payable to each Board member and alternate Board members shall be determined at the Annual General Meeting of the Company and shall be paid in accordance with payments to general employees.

Tillaga stjórnar um starfskjarastefnu, frh.

- Stjórnarmenn fá greidda fasta þöknun fyrir störf sín. Þöknun hvers stjórnarmanns og varamanna skal ákveðin á aðalfundi félagsins og greiddast í samræmi við launagreiðslur til almennra starfsmanna.



Tillögur/Proposals

Remuneration policy, cont.

- The amount payable to Board members shall be based on the responsibility involved, the complex environment the Company currently operates in, the terms generally applicable for such services in the countries in which the Company operates, and the work effort necessary.
- Proposals on the remuneration of Board members and sub-committees of the Board for the upcoming fiscal year shall be submitted to the Annual General Meeting for approval.

Tillaga stjórnar um starfskjarastefnu, frh.

- Starfskjar stjórnarmanna skulu taka mið af þeirri ábyrgð sem starfinu fylgir, því flókna umhverfi sem félagið starfar nú í, þeim kjörum sem almennt gerast um slík störf í þeim löndum sem félagið hefur starfsemi í og því vinnuframlagi sem þörf er á starfsins vegna.
- Á aðalfundi skulu bornar upp til samþykkis tillögur um launakjör stjórnar og undirnefnda félagsins fyrir komandi rekstrarár.



Tillögur/Proposals

Remuneration policy, cont.

- Terms of employment of the Company's CEO and other managing directors of the Company shall be determined by their employment contracts. The terms shall, among other things, be based on the responsibility and nature of the job in question in light of the size and extensiveness of the Company's operations, the terms generally applicable for such services in the countries in which the Company operates, and the Company's operating results.

Tillaga stjórnar um starfskjarastefnu, frh.

- Starfskjar forstjóra og annarra framkvæmdastjóra félagsins byggjast á ráðningar-samningum. Taka starfskjar þeirra m.a. mið af ábyrgð og eðli starfans í ljósi stærðar og umsvifa félagsins, þeim starfskjörum sem almennt gerast á atvinnumarkaði í þeim löndum sem félagið hefur starfsemi í, sem og rekstrarárangri félagsins.



Tillögur/Proposals

Remuneration policy, cont.

- The CEO and the managing directors of the Company may be remunerated in the form of fixed salaries, bonus payments in cash and in shares, call options, put options with respect to shares, convertible bonds, pensions and retirement payments.

Tillaga stjórnar um starfskjarastefnu, frh.

- Starfskjör forstjóra og framkvæmdastjóra félagsins geta verið samsett af föstum launum, árangurstengdum greiðslum í reiðufé og hlutabréfum, kaupréttum, sölurétti hlutabréfa, skuldabréfum með breytirétti, lífeyrisréttindum og eftirlaunaréttindum.



Tillögur/Proposals

Remuneration policy, cont.

- At the Annual General Meeting of the Company, shareholders shall be informed of the aggregate amount of salaries paid to Board members, the CEO and other managing directors of the Company in the preceding fiscal year; fixed salary, bonus payments, shares, call options, put options with respect to shares, convertible bonds, pensions and retirement payments to parties who have retired during the fiscal year.

Tillaga stjórnar um starfskjarastefnu, frh.

- Á aðalfundi félagsins skulu hluthafar upplýstir um heildarfjárhæð greiddra launa til stjórnarmanna sem og forstjóra og annarra framkvæmdastjóra á liðnu starfsári; föst laun, fjárhæð árangurstengdra launa, greiðslur í formi hlutabréfa, kaupréttá, söluréttar á hlutabréfum, skuldabréfum með breytirétti, lífeyrisréttindum og starfslokagreiðslur til þeirra sem látið hafa af störfum á starfsárinu.



Tillögur/Proposals

Authority to purchase own shares

- The Company's Board of Directors proposes that it will be authorised to purchase own shares in the Company up to an amount equivalent to 10% of the nominal value of the share capital of the Company. This authorisation shall entail that the purchase price may vary up to 5% from the pricing of shares as published in the stock exchange.

Tillaga um heimild stjórnar til kaupa á eigin hlutum

- Stjórn félagsins leggur til að henni verði veitt heimild til kaupa á eigin hlutum í félaginu þannig að eigin hlutir geti numið allt að 10% af nafnverði. Heimild stjórnar skal miðast við verð sem geti numið allt að 5% frávik frá skráðu verði hluta í félaginu í kauphöll.



Tillögur/Proposals

Amendments to the Articles of association

- Proposals on amendments to the Company's Articles of Association. The amendments mainly involve rearrangements of articles and amendments to the wording of the current Articles, but the amended Articles contain the following material amendments:
 - Article 4
 - Article 4.13
 - Article 5.1
 - Articles 5.2-5.4

Tillögur um breytingar á samþykktum félagsins

- Tillaga um nýjar samþykktir félagsins. Einkum er um að ræða endurroðun greina og breytingar á orðalagi samþykktá, en hinar nýju samþykktir fela í sér eftirfarandi efnisbreytingar:
 - Grein 4
 - Grein 4.13
 - Grein 5.1
 - Grein 5.2-5.4



Investor & media relations:

Halldor Kristmannsson Vice President
Corporate Communications

Tel : +354 535 2300/
+354 840 3425

